{"nctId":"NCT04058067","briefTitle":"To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema","startDateStruct":{"date":"2019-08-23","type":"ACTUAL"},"conditions":["Diabetic Macular Edema"],"count":266,"armGroups":[{"label":"Brolucizumab 6 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Brolucizumab"]},{"label":"Aflibercept 2 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Aflibercept"]}],"interventions":[{"name":"Brolucizumab","otherNames":["RTH258"]},{"name":"Aflibercept","otherNames":["Eylea"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Signed informed consent must be obtained prior to participation in the study.\n2. Patients ≥18 years of age at screening\n3. Patients with type 1 or type 2 diabetes mellitus (DM) and Hemoglobin A1c (HbA1c) of ≤10% at screening\n4. Medication for the management of diabetes must have been stable within 3 months prior to randomization and is expected to remain as stable as medically acceptable during the course of the study\n5. Study Eye Visual impairment due to diabetic macular edema (DME) with:\n\n   * Best-corrected visual acuity (BCVA) score between 78 and 23 letters, inclusive, using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) testing charts at a starting testing distance of 4 meters (approximate Snellen equivalent of 20/32 to 20/320) at screening and baseline\n   * DME involving the center of the macula, with central subfield retinal thickness (e.g. measured from retinal pigment epithelium (RPE) to the inner limiting membrane (ILM) inclusively) of ≥320 μm on Spectral domain optical coherence tomography (SD-OCT) at screening.\n\nExclusion Criteria:\n\n* Active Proliferative diabetic retinopathy (PDR) in the study eye as per investigator\n* Concomitant conditions or ocular disorders in the study eye at screening or baseline which could, in the opinion of the investigator, prevent response to study treatment or may confound interpretation of study results, compromise visual acuity or require medical or surgical intervention for the duration of the study (e.g. cataract, vitreous hemorrhage, retinal vascular occlusion, retinal detachment, macular hole, or choroidal neovascularization (CNV) of any cause)\n* Any active intraocular or periocular infection or active intraocular inflammation (e.g. infectious conjunctivitis, keratitis, scleritis, endophthalmitis, infectious blepharitis, uveitis) in study eye at screening or baseline\n* Structural damage of the fovea in the study eye at screening likely to preclude improvement in visual acuity following the resolution of macular edema (ME), including atrophy of the retinal pigment epithelium, subretinal fibrosis, laser scar(s), epiretinal membrane involving fovea or organized hard exudate plaques\n* Uncontrolled glaucoma in the study eye defined as intraocular pressure (IOP) \\> 25 mmHg on medication or according to investigator's judgment at Screening or Baseline\n* Neovascularization of the iris in the study eye at screening or baseline\n* Evidence of vitreomacular traction in the study eye at screening or baseline which in the opinion of the investigator, affects visual acuity\n* Previous treatment with any anti-vascular growth factor (VEGF) drug or investigational drugs in the study eye","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline at Week 52 in Best-corrected Visual Acuity (BCVA) for the Study Eye.","description":"BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts.\n\nVisual Function of the study eye was assessed using the ETDRS protocol.\n\nMin and max possible scores are 0-100 respectively. A higher score represents better visual functioning.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.6","spread":"0.85"},{"groupId":"OG001","value":"11.9","spread":"0.85"}]}]}]},{"type":"PRIMARY","title":"Best-corrected Visual Acuity (BCVA) - Average Change From Baseline Over the Period Week 40 Through Week 52 for the Study Eye","description":"BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts.\n\nVisual Function of the study eye was assessed using the ETDRS protocol.\n\nMin and max possible scores are 0-100 respectively. A higher score represents better visual functioning.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.1","spread":"0.81"},{"groupId":"OG001","value":"12.0","spread":"0.82"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline by Visit up to Week 52 in Best-corrected Visual Acuity (BCVA) for the Study Eye","description":"BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts.\n\nVisual Function of the study eye was assessed using the ETDRS protocol.\n\nMin and max possible scores are 0-100 respectively. A higher score represents better visual functioning.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":"6.58"},{"groupId":"OG001","value":"4.4","spread":"6.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.2","spread":"7.49"},{"groupId":"OG001","value":"6.6","spread":"7.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.6","spread":"8.43"},{"groupId":"OG001","value":"8.0","spread":"8.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.2","spread":"8.77"},{"groupId":"OG001","value":"9.0","spread":"9.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.0","spread":"9.83"},{"groupId":"OG001","value":"10.4","spread":"9.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.8","spread":"9.19"},{"groupId":"OG001","value":"10.7","spread":"10.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.0","spread":"9.36"},{"groupId":"OG001","value":"11.3","spread":"9.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.9","spread":"10.48"},{"groupId":"OG001","value":"10.5","spread":"9.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.5","spread":"9.62"},{"groupId":"OG001","value":"10.9","spread":"10.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.1","spread":"10.29"},{"groupId":"OG001","value":"11.3","spread":"10.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.1","spread":"10.86"},{"groupId":"OG001","value":"11.8","spread":"10.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.1","spread":"10.24"},{"groupId":"OG001","value":"11.7","spread":"10.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.2","spread":"9.86"},{"groupId":"OG001","value":"12.2","spread":"9.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.9","spread":"9.91"},{"groupId":"OG001","value":"12.2","spread":"10.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.3","spread":"9.21"},{"groupId":"OG001","value":"12.1","spread":"10.92"}]}]}]},{"type":"SECONDARY","title":"Best-corrected Visual Acuity (BCVA) - Average Change From Baseline Over the Period Week 4 Through Week 52 for the Study Eye","description":"BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts.\n\nVisual Function of the study eye was assessed using the ETDRS protocol.\n\nMin and max possible scores are 0-100 respectively. A higher score represents better visual functioning.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.0","spread":"0.68"},{"groupId":"OG001","value":"10.1","spread":"0.68"}]}]}]},{"type":"SECONDARY","title":"Best-corrected Visual Acuity (BCVA) - Average Change From Baseline Over the Period Week 20 Through Week 52 for the Study Eye","description":"BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts.\n\nVisual Function of the study eye was assessed using the ETDRS protocol.\n\nMin and max possible scores are 0-100 respectively. A higher score represents better visual functioning.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.6","spread":"0.77"},{"groupId":"OG001","value":"11.5","spread":"0.77"}]}]}]},{"type":"SECONDARY","title":"Best-corrected Visual Acuity (BCVA) - Average Change From Baseline Over the Period Week 28 Through Week 52 for the Study Eye","description":"BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts.\n\nVisual Function of the study eye was assessed using the ETDRS protocol.\n\nMin and max possible scores are 0-100 respectively. A higher score represents better visual functioning.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.6","spread":"0.80"},{"groupId":"OG001","value":"11.7","spread":"0.80"}]}]}]},{"type":"SECONDARY","title":"Time-to-first q8w Treatment Need: Summary for Brolucizumab Subjects by Disease Activity Assessment Visit","description":"The estimate for the proportion of subjects with a positive q12w treatment status was derived from Kaplan Meier time-to-event analyses for the event 'first q8w-need', applying a 'q8w-need' allocation in case of missing or confounded data attributable to lack of efficacy and/or lack of safety. As a result, the probability that subjects in brolucizumab arm do not need a q8w treatment (and therefore are maintained on a q12w treatment) up to the visit is reported in the table.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.733","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.447","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.417","spread":null}]}]}]},{"type":"SECONDARY","title":"Time-to-first q8w Treatment Need: Summary for Brolucizumab Subjects by Disease Activity Assessment Visit, Within Those Subjects With no q8w-need During the Initial q12w Cycle","description":"The estimate for the proportion of subjects with a positive q12w treatment status was derived from Kaplan Meier time-to-event analyses for the event 'first q8w-need', applying a 'q8w-need' allocation in case of missing or confounded data attributable to lack of efficacy and/or lack of safety. As a result, the probability that subjects in brolucizumab arm do not need a q8w treatment (and therefore are maintained on a q12w treatment) up to the visit is reported in the table.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.931","spread":null}]}]}]},{"type":"SECONDARY","title":"Number and Percentage of Patients Who Gained in ≥5, ≥10 and ≥15 ETDRS Letters in BCVA From Baseline to Week 52 for the Study Eye","description":"BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts.\n\nVisual Function of the study eye was assessed using the ETDRS protocol.\n\nMin and max possible scores are 0-100 respectively. A higher score represents better visual functioning.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":null},{"groupId":"OG001","value":"104","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"48","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Achieve Gain of >= 5 Letters in BCVA From Baseline or Reach BCVA >=84 Letters for the Study Eye - Probability of BCVA Gain","description":"BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts.\n\nVisual Function of the study eye was assessed using the ETDRS protocol.\n\nMin and max possible scores are 0-100 respectively. A higher score represents better visual functioning.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.136","spread":null},{"groupId":"OG001","value":"0.038","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.508","spread":null},{"groupId":"OG001","value":"0.420","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.720","spread":null},{"groupId":"OG001","value":"0.634","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.780","spread":null},{"groupId":"OG001","value":"0.725","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.818","spread":null},{"groupId":"OG001","value":"0.780","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.818","spread":null},{"groupId":"OG001","value":"0.843","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.841","spread":null},{"groupId":"OG001","value":"0.866","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.856","spread":null},{"groupId":"OG001","value":"0.874","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.864","spread":null},{"groupId":"OG001","value":"0.882","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.888","spread":null},{"groupId":"OG001","value":"0.882","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.888","spread":null},{"groupId":"OG001","value":"0.882","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.888","spread":null},{"groupId":"OG001","value":"0.908","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.896","spread":null},{"groupId":"OG001","value":"0.908","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.912","spread":null},{"groupId":"OG001","value":"0.917","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.957","spread":null},{"groupId":"OG001","value":"0.926","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Achieve Gain of >= 10 Letters in BCVA From Baseline or Reach BCVA >=84 Letters for the Study Eye - Probability of BCVA Gain","description":"BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts.\n\nVisual Function of the study eye was assessed using the ETDRS protocol.\n\nMin and max possible scores are 0-100 respectively. A higher score represents better visual functioning.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.061","spread":null},{"groupId":"OG001","value":"0.000","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.227","spread":null},{"groupId":"OG001","value":"0.198","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.394","spread":null},{"groupId":"OG001","value":"0.306","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.508","spread":null},{"groupId":"OG001","value":"0.439","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.562","spread":null},{"groupId":"OG001","value":"0.527","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.594","spread":null},{"groupId":"OG001","value":"0.551","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.618","spread":null},{"groupId":"OG001","value":"0.591","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.643","spread":null},{"groupId":"OG001","value":"0.664","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.659","spread":null},{"groupId":"OG001","value":"0.680","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.676","spread":null},{"groupId":"OG001","value":"0.705","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.693","spread":null},{"groupId":"OG001","value":"0.722","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.710","spread":null},{"groupId":"OG001","value":"0.730","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.728","spread":null},{"groupId":"OG001","value":"0.739","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.754","spread":null},{"groupId":"OG001","value":"0.749","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.899","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Achieve Gain of >= 15 Letters in BCVA From Baseline or Reach BCVA >=84 Letters for the Study Eye - Probability of BCVA Gain","description":"BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts.\n\nVisual Function of the study eye was assessed using the ETDRS protocol.\n\nMin and max possible scores are 0-100 respectively. A higher score represents better visual functioning.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.008","spread":null},{"groupId":"OG001","value":"0.000","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.083","spread":null},{"groupId":"OG001","value":"0.069","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.152","spread":null},{"groupId":"OG001","value":"0.161","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.227","spread":null},{"groupId":"OG001","value":"0.216","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.266","spread":null},{"groupId":"OG001","value":"0.255","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.313","spread":null},{"groupId":"OG001","value":"0.319","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.344","spread":null},{"groupId":"OG001","value":"0.359","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.409","spread":null},{"groupId":"OG001","value":"0.399","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.425","spread":null},{"groupId":"OG001","value":"0.432","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.459","spread":null},{"groupId":"OG001","value":"0.456","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.485","spread":null},{"groupId":"OG001","value":"0.481","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.494","spread":null},{"groupId":"OG001","value":"0.506","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.512","spread":null},{"groupId":"OG001","value":"0.531","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.539","spread":null},{"groupId":"OG001","value":"0.540","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.623","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number and Percentage of Patients Who Lost ≥5, ≥10 and ≥15 ETDRS Letters in BCVA From Baseline to Week 52 for the Study Eye","description":"BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts.\n\nVisual Function of the study eye was assessed using the ETDRS protocol.\n\nMin and max possible scores are 0-100 respectively. A higher score represents better visual functioning.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients Who Have Absolute BCVA ≥73 ETDRS Letters at Each Post-baseline Visit for the Study Eye","description":"BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts.\n\nVisual Function of the study eye was assessed using the ETDRS protocol.\n\nMin and max possible scores are 0-100 respectively. A higher score represents better visual functioning.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"81","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"75","spread":null}]}]}]},{"type":"SECONDARY","title":"Number (%) of Subjects With q8w Treatment Need as Assessed by the Investigator at First Disease Activity Assessment (DAA) Visit - Week 32","description":"To evaluate the efficacy related to dosing regimen of brolucizumab","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]}]},{"type":"SECONDARY","title":"Number (%) of Subjects With q8w Treatment Need as Assessed by the Investigator at Week 36, and Week 48","description":"To evaluate the efficacy related to dosing regimen of brolucizumab","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline at Week 52 in Central Subfield Thickness (CSFT) for the Study Eye","description":"Central Subfield Thickness Assessed by Spectral domain optical coherence tomography (SD-OCT) from the central reading center.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-225.2","spread":"9.71"},{"groupId":"OG001","value":"-215.0","spread":"9.75"}]}]}]},{"type":"SECONDARY","title":"Average Change From Baseline Over the Period Week 40 Through Week 52 in Central Subfield Thickness (CSFT) for the Study Eye","description":"Central Subfield Thickness Assessed by Spectral domain optical coherence tomography (SD-OCT) from the central reading center.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-215.1","spread":"8.69"},{"groupId":"OG001","value":"-212.7","spread":"8.73"}]}]}]},{"type":"SECONDARY","title":"Average Change From Baseline Over the Period Week 4 Through Week 52 in Central Subfield Thickness (CSFT) for the Study Eye","description":"Central Subfield Thickness Assessed by Spectral domain optical coherence tomography (SD-OCT) from the central reading center.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-207.7","spread":"7.77"},{"groupId":"OG001","value":"-199.2","spread":"7.80"}]}]}]},{"type":"SECONDARY","title":"Number and Percentage of Patients Who Have CSFT (<280 Microns) at Each Assessment Visit for the Study Eye","description":"Central Subfield Thickness Assessed by Spectral domain optical coherence tomography (SD-OCT) from the central reading center.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null},{"groupId":"OG001","value":"56","spread":null}]}]}]},{"type":"SECONDARY","title":"Number (%) of Patients With Progression to Proliferative Diabetic Retinopathy (PDR) as Assessed by ETDRS DRSS of at Least 61 by Week 52 for the Study Eye Among the Subset of Non-PDR Subjects at Screening","description":"As evaluated using the Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) score assessed by the Central Reading Center (CRC) based on color fundus photography images in the study eye.\n\nWhen the ETDRS-DR severities were evaluable, they were converted and categorized on a 12-level scale, from 1 (DR absent) to 12 (very advanced PDR). A lower score represents better visual functioning.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number (%) of Patients With Presence of Leakage in the Study Eye on Fluorescein Angiography (FA)","description":"Assessed by angiography.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"110","spread":null},{"groupId":"OG001","value":"115","spread":null}]}]}]},{"type":"SECONDARY","title":"Number (%) of Patients With Presence of Subretinal Fluid (SRF), Intraretinal Fluid (IRF) in the Study Eye","description":"To evaluate the efficacy of brolucizumab relative to aflibercept over the time period by assessing changes in anatomical parameters","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"85","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Presence of Subretinal Fluid (SRF) in the Study at Each Assessment Visit","description":"Subretinal Fluid (SRF) status in the central subfield: proportion of subjects with presence of SRF in the study eye by visit","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Presence of Intraretinal Fluid (IRF) in the Study at Each Assessment Visit","description":"Intraretinal Fluid (IRF) status in the central subfield: proportion of subjects with presence of IRF in the study eye by visit","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"113","spread":null},{"groupId":"OG001","value":"115","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"112","spread":null},{"groupId":"OG001","value":"110","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"109","spread":null},{"groupId":"OG001","value":"112","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"110","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null},{"groupId":"OG001","value":"109","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"110","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"102","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null},{"groupId":"OG001","value":"102","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null},{"groupId":"OG001","value":"101","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null},{"groupId":"OG001","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"85","spread":null}]}]}]},{"type":"SECONDARY","title":"Intraretinal Fluid (IRF) Status in the Central Subfield: Proportion of Subjects With Presence of IRF in the Study Eye by Visit","description":"Subretinal Fluid (SRF) and Intraretinal Fluid (IRF) status in the central subfield: proportion of subjects with presence of SRF and/or IRF in the study eye by visit","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"117","spread":null},{"groupId":"OG001","value":"118","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"113","spread":null},{"groupId":"OG001","value":"114","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"111","spread":null},{"groupId":"OG001","value":"114","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"110","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null},{"groupId":"OG001","value":"110","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"110","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"102","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null},{"groupId":"OG001","value":"102","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null},{"groupId":"OG001","value":"101","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null},{"groupId":"OG001","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"85","spread":null}]}]}]},{"type":"SECONDARY","title":"Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS): Number of Subjects With >=2-step Improvement From Baseline in the DRSS Score at Each Assessment Visit for the Study Eye - Number of Subjects","description":"Severity of Diabetic Retinopathy (DR) was evaluated using the ETDRS DRSS score assessed by the Central Reading Center (CRC) based on color fundus photography images in the study eye. When the ETDRS-DR severities were evaluable, they were categorized on a 12-level scale, from 1 (DR absent) to 12 (very advanced PDR). A lower score represents better visual functioning.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"64","spread":null}]}]}]},{"type":"SECONDARY","title":"Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS): Proportion of Subjects With >=2-step Improvement From Baseline in the DRSS Score at Each Assessment Visit for the Study Eye - Percentage Estimates","description":"Severity of Diabetic Retinopathy (DR) was evaluated using the ETDRS DRSS score assessed by the Central Reading Center (CRC) based on color fundus photography images in the study eye. When the ETDRS-DR severities were evaluable, they were categorized on a 12-level scale, from 1 (DR absent) to 12 (very advanced PDR). A lower score represents better visual functioning.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.9","spread":null},{"groupId":"OG001","value":"36.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.7","spread":null},{"groupId":"OG001","value":"49.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS): Number of Subjects With >=3-step Improvement From Baseline in the DRSS Score at Each Assessment Visit for the Study Eye - Number of Subjects","description":"Severity of Diabetic Retinopathy (DR) was evaluated using the ETDRS DRSS score assessed by the Central Reading Center (CRC) based on color fundus photography images in the study eye. When the ETDRS-DR severities were evaluable, they were categorized on a 12-level scale, from 1 (DR absent) to 12 (very advanced PDR). A lower score represents better visual functioning.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]}]},{"type":"SECONDARY","title":"Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS): Proportion of Subjects With >=3-step Improvement From Baseline in the DRSS Score at Each Assessment Visit for the Study Eye - Percentage Estimates","description":"Severity of Diabetic Retinopathy (DR) was evaluated using the ETDRS DRSS score assessed by the Central Reading Center (CRC) based on color fundus photography images in the study eye. When the ETDRS-DR severities were evaluable, they were categorized on a 12-level scale, from 1 (DR absent) to 12 (very advanced PDR). A lower score represents better visual functioning.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.8","spread":null},{"groupId":"OG001","value":"11.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.8","spread":null},{"groupId":"OG001","value":"19.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS): Number of Subjects With >=2-step Worsening From Baseline in the DRSS Score at Each Assessment Visit for the Study Eye - Number of Subjects","description":"Severity of Diabetic Retinopathy (DR) was evaluated using the ETDRS DRSS score assessed by the Central Reading Center (CRC) based on color fundus photography images in the study eye. When the ETDRS-DR severities were evaluable, they were categorized on a 12-level scale, from 1 (DR absent) to 12 (very advanced PDR). A lower score represents better visual functioning.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS): Proportion of Subjects With >=2-step Worsening From Baseline in the DRSS Score at Each Assessment Visit for the Study Eye - Percentage Estimates","description":"Severity of Diabetic Retinopathy (DR) was evaluated using the ETDRS DRSS score assessed by the Central Reading Center (CRC) based on color fundus photography images in the study eye. When the ETDRS-DR severities were evaluable, they were categorized on a 12-level scale, from 1 (DR absent) to 12 (very advanced PDR). A lower score represents better visual functioning.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[]}]},{"type":"SECONDARY","title":"Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS): Number of Subjects With >=3-step Worsening From Baseline in the DRSS Score at Each Assessment Visit for the Study Eye - Number of Subjects","description":"Severity of Diabetic Retinopathy (DR) was evaluated using the ETDRS DRSS score assessed by the Central Reading Center (CRC) based on color fundus photography images in the study eye. When the ETDRS-DR severities were evaluable, they were categorized on a 12-level scale, from 1 (DR absent) to 12 (very advanced PDR). A lower score represents better visual functioning.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS): Proportion of Subjects With >=3-step Worsening From Baseline in the DRSS Score at Each Assessment Visit for the Study Eye - Percentage Estimates","description":"Severity of Diabetic Retinopathy (DR) was evaluated using the ETDRS DRSS score assessed by the Central Reading Center (CRC) based on color fundus photography images in the study eye. When the ETDRS-DR severities were evaluable, they were categorized on a 12-level scale, from 1 (DR absent) to 12 (very advanced PDR). A lower score represents better visual functioning.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[]}]},{"type":"SECONDARY","title":"Change From Baseline at Week 28 and Week 52 in Patient Reported Outcomes (Visual Function Questionnaire-25) - Overall Score","description":"The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) measures the influence of visual disability and visual symptoms on general health domains.\n\nThe NEI VFQ-25 consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. All items are scored so that a high score represents better visual functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. A composite score is derived based on the average of the 11 subscales.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":"11.97"},{"groupId":"OG001","value":"7.7","spread":"15.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":"13.87"},{"groupId":"OG001","value":"6.6","spread":"16.50"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline at Week 28 and Week 52 in Patient Reported Outcomes (Visual Function Questionnaire-25) - General Vision","description":"The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) measures the influence of visual disability and visual symptoms on general health domains.\n\nThe NEI VFQ-25 consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. All items are scored so that a high score represents better visual functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. A composite score is derived based on the average of the 11 subscales.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.4","spread":"18.80"},{"groupId":"OG001","value":"9.5","spread":"18.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.9","spread":"18.23"},{"groupId":"OG001","value":"11.5","spread":"17.74"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline at Week 28 and Week 52 in Patient Reported Outcomes (Visual Function Questionnaire-25) - Ocular Pain","description":"The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) measures the influence of visual disability and visual symptoms on general health domains.\n\nThe NEI VFQ-25 consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. All items are scored so that a high score represents better visual functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. A composite score is derived based on the average of the 11 subscales.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":"20.16"},{"groupId":"OG001","value":"5.3","spread":"24.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":"22.51"},{"groupId":"OG001","value":"2.6","spread":"25.27"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline at Week 28 and Week 52 in Patient Reported Outcomes (Visual Function Questionnaire-25) - Near Activities","description":"The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) measures the influence of visual disability and visual symptoms on general health domains.\n\nThe NEI VFQ-25 consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. All items are scored so that a high score represents better visual functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. A composite score is derived based on the average of the 11 subscales.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.5","spread":"20.79"},{"groupId":"OG001","value":"9.7","spread":"24.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.8","spread":"22.12"},{"groupId":"OG001","value":"8.0","spread":"25.25"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline at Week 28 and Week 52 in Patient Reported Outcomes (Visual Function Questionnaire-25) - Distance Activities","description":"The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) measures the influence of visual disability and visual symptoms on general health domains.\n\nThe NEI VFQ-25 consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. All items are scored so that a high score represents better visual functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. A composite score is derived based on the average of the 11 subscales.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":"17.54"},{"groupId":"OG001","value":"7.6","spread":"22.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":"18.42"},{"groupId":"OG001","value":"6.5","spread":"22.43"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline at Week 28 and Week 52 in Patient Reported Outcomes (Visual Function Questionnaire-25) - Social Functioning","description":"The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) measures the influence of visual disability and visual symptoms on general health domains.\n\nThe NEI VFQ-25 consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. All items are scored so that a high score represents better visual functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. A composite score is derived based on the average of the 11 subscales.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":"14.86"},{"groupId":"OG001","value":"5.2","spread":"18.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":"15.47"},{"groupId":"OG001","value":"5.8","spread":"17.73"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline at Week 28 and Week 52 in Patient Reported Outcomes (Visual Function Questionnaire-25) - Mental Health","description":"The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) measures the influence of visual disability and visual symptoms on general health domains.\n\nThe NEI VFQ-25 consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. All items are scored so that a high score represents better visual functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. A composite score is derived based on the average of the 11 subscales.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.2","spread":"23.94"},{"groupId":"OG001","value":"8.4","spread":"26.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","spread":"27.94"},{"groupId":"OG001","value":"6.7","spread":"27.84"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline at Week 28 and Week 52 in Patient Reported Outcomes (Visual Function Questionnaire-25) - Dependency","description":"The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) measures the influence of visual disability and visual symptoms on general health domains.\n\nThe NEI VFQ-25 consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. All items are scored so that a high score represents better visual functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. A composite score is derived based on the average of the 11 subscales.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"27.90"},{"groupId":"OG001","value":"9.2","spread":"29.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":"30.77"},{"groupId":"OG001","value":"5.7","spread":"33.73"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline at Week 28 and Week 52 in Patient Reported Outcomes (Visual Function Questionnaire-25) - Driving","description":"The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) measures the influence of visual disability and visual symptoms on general health domains.\n\nThe NEI VFQ-25 consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. All items are scored so that a high score represents better visual functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. A composite score is derived based on the average of the 11 subscales.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.4","spread":"11.69"},{"groupId":"OG001","value":"9.8","spread":"23.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"10.91"},{"groupId":"OG001","value":"6.0","spread":"23.59"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline at Week 28 and Week 52 in Patient Reported Outcomes (Visual Function Questionnaire-25) - Color Vision","description":"The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) measures the influence of visual disability and visual symptoms on general health domains.\n\nThe NEI VFQ-25 consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. All items are scored so that a high score represents better visual functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. A composite score is derived based on the average of the 11 subscales.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"17.22"},{"groupId":"OG001","value":"3.0","spread":"19.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":"17.27"},{"groupId":"OG001","value":"3.3","spread":"17.47"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline at Week 28 and Week 52 in Patient Reported Outcomes (Visual Function Questionnaire-25) - Peripheral Vision","description":"The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) measures the influence of visual disability and visual symptoms on general health domains.\n\nThe NEI VFQ-25 consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. All items are scored so that a high score represents better visual functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. A composite score is derived based on the average of the 11 subscales.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":"14.20"},{"groupId":"OG001","value":"7.5","spread":"20.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":"19.69"},{"groupId":"OG001","value":"7.7","spread":"19.92"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline at Week 28 and Week 52 in Patient Reported Outcomes (Visual Function Questionnaire-25) - General Health Rating","description":"The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) measures the influence of visual disability and visual symptoms on general health domains.\n\nThe NEI VFQ-25 consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. All items are scored so that a high score represents better visual functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. A composite score is derived based on the average of the 11 subscales.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":"26.47"},{"groupId":"OG001","value":"2.2","spread":"26.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":"26.24"},{"groupId":"OG001","value":"-0.2","spread":"26.34"}]}]}]},{"type":"SECONDARY","title":"Brolucizumab Serum Concentration","description":"To confirm the systemic brolucizumab exposure in a subset of patients.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.1","spread":"4.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.4","spread":"4.81"}]}]}]},{"type":"SECONDARY","title":"Number (%) of Patients Who Have Positive Anti-drug Antibody (ADA) Status in Brolucizumab Arm","description":"To assess the immunogenicity of brolucizumab","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Ocular Adverse Events (AEs) (>=2% in Any Treatment Arm) by Preferred Term for the Study Eye","description":"An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \\[including abnormal laboratory findings\\], symptom or disease) in a subject or clinical investigation subject","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Non-ocular Adverse Events (AEs) (>=2% in Any Treatment Arm)","description":"An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \\[including abnormal laboratory findings\\], symptom or disease) in a subject or clinical investigation subject","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"74","spread":null}]}]}]},{"type":"POST_HOC","title":"All Collected Deaths","description":"On-treatment deaths are reported from first dose of study treatment until end of study treatment plus 4 weeks post treatment, up to a maximum timeframe of approximately 52 weeks. Post-treatment deaths are reported for the timeframe of greater than 30 days after last treatment, until study completion, up to Week 52. All deaths refer to the sum of on-treatment and post-treatment deaths.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":28,"n":132},"commonTop":["Hyperlipidaemia","Hypertension","Visual acuity reduced - Fellow eye","Visual acuity reduced - Study eye","Upper respiratory tract infection"]}}}